inkretinový

Inkretinový is a term derived from the Latin word "incretum," which means "to grow together." It is used in the context of biology and medicine to describe substances that stimulate the release of insulin from the pancreas. These substances, known as incretins, are produced in the gut in response to the ingestion of food and play a crucial role in regulating blood sugar levels.

The primary incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 is released from the intestinal L-cells in response to the presence of glucose and amino acids in the gut. It acts on the pancreas to stimulate the release of insulin, which helps to lower blood sugar levels. GIP is released from the intestinal K-cells and also stimulates insulin release, although its primary effect is to promote the absorption of glucose from the intestines.

Inkretin-based therapies are a class of medications used to treat type 2 diabetes. These therapies mimic the action of natural incretins by stimulating insulin release and reducing glucagon release, thereby improving blood sugar control. Examples of inkretin-based therapies include exenatide (Byetta, Bydureon) and liraglutide (Victoza, Saxenda).

The use of inkretin-based therapies has been associated with several benefits, including improved glycemic control, weight loss, and a reduced risk of hypoglycemia. However, they may also have side effects such as nausea, vomiting, and injection site reactions. As with any medication, the use of inkretin-based therapies should be carefully considered and monitored by a healthcare provider.